Venu Krishna, Barclays Managing Director & Head of U.S. Equity Strategy, joins 'Fast Money' to talk the recent market rally, what it means for investing at this point, and more. Supreme Court hands ...

Democrats are laying the groundwork to oppose a photo ID bill Republicans will bring to the Senate floor Thursday, arguing that voting laws are best left to the states or that the legislation before ...

De'Anthony Melton hit the go-ahead free throw with 24.5 seconds left in the Golden State Warriors' 109-106 win over the Brooklyn Nets at Chase Center on Wednesday night. With the game tied at 106-106, ...

Jeffrey Gundlach, DoubleLine Capital founder and CEO, joins 'Closing Bell' to discuss Gundlach's broad view on equity markets, the commodity complex and much more. Breaking: Trump says 'effective ...

Time: 08:00–09:00 PDT, 11:00–12:00 EDT, 17:00–18:00 CEST California regulators are raising the bar on what it truly means to honor consumer opt-out rights. Posting a "Do Not Sell or Share" link is no ...

This AAAS program will allow the Graduate School to better target students with disabilities for its longstanding SMART program The Graduate School’s Office of Graduate Access and Retention (GAR) is ...

(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro. See the full discussion above.) Investor Jay Woods is keeping a close eye on ...

Walmart is aggressively integrating AI, notably Sparky, to drive operational efficiency and profitability, narrowing the gap with Amazon. Despite recent e-commerce profitability and 8% operating ...

Initiates first-in-human clinical studies of an IgG-like CD3 bispecific designed with a wide therapeutic index to selectively redirect T cells to B7-H7–expressing tumors, including lung adenocarcinoma ...

NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors Initiates first-in-human clinical studies of an IgG-like CD3 bispecific ...